These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 7856085)

  • 1. Identification of structural features of heparin required for inhibition of herpes simplex virus type 1 binding.
    Herold BC; Gerber SI; Polonsky T; Belval BJ; Shaklee PN; Holme K
    Virology; 1995 Feb; 206(2):1108-16. PubMed ID: 7856085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differences in the susceptibility of herpes simplex virus types 1 and 2 to modified heparin compounds suggest serotype differences in viral entry.
    Herold BC; Gerber SI; Belval BJ; Siston AM; Shulman N
    J Virol; 1996 Jun; 70(6):3461-9. PubMed ID: 8648678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neomycin inhibits glycoprotein C (gC)-dependent binding of herpes simplex virus type 1 to cells and also inhibits postbinding events in entry.
    Herold BC; Spear PG
    Virology; 1994 Aug; 203(1):166-71. PubMed ID: 8030274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modified entry and syncytium formation by herpes simplex virus type 1 mutants selected for resistance to heparin inhibition.
    Pertel PE; Spear PG
    Virology; 1996 Dec; 226(1):22-33. PubMed ID: 8941319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell-specific kinetics and efficiency of herpes simplex virus type 1 entry are determined by two distinct phases of attachment.
    McClain DS; Fuller AO
    Virology; 1994 Feb; 198(2):690-702. PubMed ID: 8291250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural and functional features of the polycationic peptide required for inhibition of herpes simplex virus invasion of cells.
    Trybala E; Olofsson S; Mårdberg K; Svennerholm B; Umemoto K; Glorioso JC; Bergström T
    Antiviral Res; 2004 Jun; 62(3):125-34. PubMed ID: 15130536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of herpes simplex virus type 1 recombinants that express and incorporate high levels of HCV E2-gC chimeric proteins.
    Kouvatsis V; Argnani R; Tsitoura E; Arsenakis M; Georgopoulou U; Mavromara P; Manservigi R
    Virus Res; 2007 Jan; 123(1):40-9. PubMed ID: 16989918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An alpha-helical domain within the carboxyl terminus of herpes simplex virus type 1 (HSV-1) glycoprotein B (gB) is associated with cell fusion and resistance to heparin inhibition of cell fusion.
    Foster TP; Melancon JM; Kousoulas KG
    Virology; 2001 Aug; 287(1):18-29. PubMed ID: 11504538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kinetic analysis of glycoprotein C of herpes simplex virus types 1 and 2 binding to heparin, heparan sulfate, and complement component C3b.
    Rux AH; Lou H; Lambris JD; Friedman HM; Eisenberg RJ; Cohen GH
    Virology; 2002 Mar; 294(2):324-32. PubMed ID: 12009874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence for an interaction of herpes simplex virus with chondroitin sulfate proteoglycans during infection.
    Banfield BW; Leduc Y; Esford L; Visalli RJ; Brandt CR; Tufaro F
    Virology; 1995 Apr; 208(2):531-9. PubMed ID: 7747425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of glycoproteins B, C and D on the conversion of virus-to-cell attachment from heparin sensitivity to resistance.
    Seck T; Koch O; Lingen M; Falke D
    Acta Virol; 1996 Sep; 40(4):179-85. PubMed ID: 9014007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The polysulfonated compound suramin blocks adsorption and lateral difusion of herpes simplex virus type-1 in vero cells.
    Aguilar JS; Rice M; Wagner EK
    Virology; 1999 May; 258(1):141-51. PubMed ID: 10329576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences in the role of glycoprotein C of HSV-1 and HSV-2 in viral binding may contribute to serotype differences in cell tropism.
    Gerber SI; Belval BJ; Herold BC
    Virology; 1995 Dec; 214(1):29-39. PubMed ID: 8525631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Herpes simplex virus glycoprotein B binds to cell surfaces independently of heparan sulfate and blocks virus entry.
    Bender FC; Whitbeck JC; Lou H; Cohen GH; Eisenberg RJ
    J Virol; 2005 Sep; 79(18):11588-97. PubMed ID: 16140736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A wide range of medium-sized, highly cationic, alpha-helical peptides show antiviral activity against herpes simplex virus.
    Jenssen H; Andersen JH; Mantzilas D; Gutteberg TJ
    Antiviral Res; 2004 Nov; 64(2):119-26. PubMed ID: 15498607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycosaminoglycans are not indispensable for the anti-herpes simplex virus type 2 activity of lactoferrin.
    Marchetti M; Ammendolia MG; Superti F
    Biochimie; 2009 Jan; 91(1):155-9. PubMed ID: 18534197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human herpesvirus 8 interaction with target cells involves heparan sulfate.
    Akula SM; Wang FZ; Vieira J; Chandran B
    Virology; 2001 Apr; 282(2):245-55. PubMed ID: 11289807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The identification and characterization of fusogenic domains in herpes virus glycoprotein B molecules.
    Galdiero S; Vitiello M; D'Isanto M; Falanga A; Cantisani M; Browne H; Pedone C; Galdiero M
    Chembiochem; 2008 Mar; 9(5):758-67. PubMed ID: 18311743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Herpes simplex virus type 1 variants arising after selection with an antiviral carrageenan: lack of correlation between drug susceptibility and syn phenotype.
    Carlucci MJ; Scolaro LA; Damonte EB
    J Med Virol; 2002 Sep; 68(1):92-8. PubMed ID: 12210435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heparan sulfate proteoglycan binding by herpes simplex virus type 1 glycoproteins B and C, which differ in their contributions to virus attachment, penetration, and cell-to-cell spread.
    Laquerre S; Argnani R; Anderson DB; Zucchini S; Manservigi R; Glorioso JC
    J Virol; 1998 Jul; 72(7):6119-30. PubMed ID: 9621076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.